IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

IAVARONE, MASSIMO ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.883
AS - Asia 7.281
NA - Nord America 7.218
SA - Sud America 692
AF - Africa 150
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 7
Totale 25.277
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.907
GB - Regno Unito 3.765
CN - Cina 2.350
SG - Singapore 1.926
IT - Italia 1.417
DE - Germania 1.229
SE - Svezia 737
RU - Federazione Russa 648
HK - Hong Kong 614
BD - Bangladesh 552
VN - Vietnam 503
BR - Brasile 477
FR - Francia 465
IN - India 375
UA - Ucraina 310
IE - Irlanda 285
NL - Olanda 262
TR - Turchia 230
FI - Finlandia 213
KR - Corea 204
CA - Canada 193
JP - Giappone 130
PL - Polonia 116
EU - Europa 112
DK - Danimarca 91
CO - Colombia 88
ES - Italia 84
TW - Taiwan 83
ID - Indonesia 78
GR - Grecia 70
MX - Messico 65
AR - Argentina 52
AU - Australia 38
CI - Costa d'Avorio 36
CH - Svizzera 28
BE - Belgio 27
PK - Pakistan 26
UZ - Uzbekistan 25
AT - Austria 24
EG - Egitto 24
IQ - Iraq 23
CL - Cile 20
TH - Thailandia 20
RO - Romania 18
SA - Arabia Saudita 18
ZA - Sudafrica 17
PH - Filippine 16
EC - Ecuador 15
VE - Venezuela 15
JO - Giordania 14
PT - Portogallo 14
IL - Israele 13
PE - Perù 12
CZ - Repubblica Ceca 11
LT - Lituania 11
MA - Marocco 11
MY - Malesia 11
SL - Sierra Leone 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
JM - Giamaica 9
PA - Panama 9
IR - Iran 8
KZ - Kazakistan 7
LU - Lussemburgo 7
NO - Norvegia 7
NZ - Nuova Zelanda 7
PY - Paraguay 7
RS - Serbia 7
TN - Tunisia 7
AZ - Azerbaigian 6
HU - Ungheria 6
NP - Nepal 6
SC - Seychelles 6
TT - Trinidad e Tobago 6
CR - Costa Rica 5
EE - Estonia 5
KE - Kenya 5
KH - Cambogia 5
MM - Myanmar 5
SI - Slovenia 5
UY - Uruguay 5
BG - Bulgaria 4
BY - Bielorussia 4
ET - Etiopia 4
GH - Ghana 4
MD - Moldavia 4
PS - Palestinian Territory 4
SN - Senegal 4
BB - Barbados 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
PR - Porto Rico 3
QA - Qatar 3
AL - Albania 2
AO - Angola 2
BS - Bahamas 2
GE - Georgia 2
Totale 25.343
Salva come PNG Salva come JPEG
Città #
Southend 3.559
Singapore 1.138
Ashburn 738
Chandler 561
Hong Kong 547
Frankfurt am Main 466
Beijing 465
Milan 386
San Jose 371
Seattle 330
Dublin 271
Dallas 254
Jacksonville 244
Princeton 243
Los Angeles 230
Council Bluffs 217
Wilmington 211
New York 189
Santa Clara 167
Nanjing 153
Ann Arbor 152
Bengaluru 152
Ho Chi Minh City 151
Hanoi 134
Houston 131
Lauterbourg 126
Fairfield 125
Shanghai 112
Hefei 108
Dearborn 107
Mountain View 106
Buffalo 105
Redmond 105
Guangzhou 103
Toronto 102
Helsinki 100
Moscow 100
Warsaw 100
Boardman 99
Woodbridge 99
Rome 90
Serra 84
Des Moines 80
Bogotá 74
Andover 72
Sakarya 69
Munich 68
Columbus 62
Tokyo 60
Chicago 57
São Paulo 57
Jinan 54
Somerville 54
Tianjin 53
Turin 52
Athens 51
Phoenix 48
Shenyang 47
Redwood City 46
Grafing 45
Changsha 43
Shenzhen 43
Cambridge 42
Jakarta 41
Hangzhou 40
Abidjan 36
Berlin 36
Nanchang 34
Mumbai 32
Istanbul 31
Saint Petersburg 31
The Dalles 31
Da Nang 30
Seoul 30
Cangzhou 29
Bologna 28
Fuzhou 28
Zhengzhou 28
Haiphong 27
Naples 27
Taipei 27
Hanover 26
Madrid 26
Montreal 25
Hebei 23
Taichung 23
Belo Horizonte 22
Brooklyn 22
Brussels 22
Kunming 22
London 22
San Diego 22
Bitonto 20
Bari 19
Nuremberg 19
Atlanta 18
Orem 18
Piscataway 18
Düsseldorf 17
Eitensheim 17
Totale 15.375
Salva come PNG Salva come JPEG
Nome #
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL) : a randomised, controlled, phase 2b/3 trial 876
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs 626
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 529
Multimodality treatment of hepatocellular carcinoma : How field practice complies with international recommendations 468
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 431
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment 395
Experience Wwith Early Sorafenib Treatment with Mtor Inhibitors in Hepatocellular Carcinoma Recurring after Liver Transplantation 372
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance 327
High rates of 30-day mortality in patients with cirrhosis and COVID-19 312
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B 311
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 303
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 287
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 287
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma 282
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 279
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation 264
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 257
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 256
Assessing tumor angiogenesis : Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells 251
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy 250
Serum expression of lectin reactive alphafetoprotein, des-gamma-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma 246
A prospective study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of hepatocellular carcinoma 246
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma 246
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 243
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 238
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 238
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 234
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 233
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy 226
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 225
Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension 223
TLL1 Variants do not predict hepatocellular carcinoma development in hcv cirrhotic patients treated with direct-acting antivirals 221
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 217
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 216
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib 216
Recist versus easl criteria for the evaluation of HCC response to sorafenib 212
Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature 210
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 208
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 208
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 207
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib 206
The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma 205
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 204
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 204
Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant : An Italian Multicenter Experience 204
Prevalence and natural history of portal vein thrombosis, evaluated by contrast enhanced ultrasonography (CEUS), in patients with hepatocellular carcinoma 203
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 198
Natural history of de-novo portal vein thrombosis in patients with hepatocellular carcinoma 197
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis 197
Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics 197
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 196
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 194
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 193
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 193
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma 193
Management of hepatocellular carcinoma in the time of COVID-19 192
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 188
Interventional radiology image-guided locoregional therapies (Lrts) and immunotherapy for the treatment of hcc 188
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 186
Prospective validation of immunohistological stain for glypican-3 (GPC-3) in the early diagnosis of hepatocellular carcinoma 186
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 186
Chemoembolization with epirubicin drug eluting beads to treat early and intermediate hepatocellular carcinoma 183
Reshape and secure HCC managing during COVID-19 pandemic : A single centre analysis of four periods in 2020 versus 2019 180
Clinical Impact of a Protocol Involving Cone-Beam CT (CBCT), Fusion Imaging and Ablation Volume Prediction in Percutaneous Image-Guided Microwave Ablation in Patients with Hepatocellular Carcinoma Unsuitable for Standard Ultrasound (US) Guidance 178
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 176
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 176
Field practice with sorafenib in advanced HCC : effectiveness confirmed, reduced tolerability compared to registration trials 175
A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene 175
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 174
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 174
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 174
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 173
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 173
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US) 168
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 168
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 167
Induced myocardial ischemia in candidates to liver transplantation without evidence of heart disease 166
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis 166
Transarterial embolization with microspheres in the treatment of monofocal HCC 165
The natural history of macroregenerative nodules prospectively detected in cirrhotic patients under surveillance 164
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients 164
Prospective validation of immunohistological stain for glypican-3 (GPC-3) in the early diagnosis of hepatocellular carcinoma 163
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib : The ALICE-1 study 161
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis 159
Global Antiviral Journal “Bridging the Sciencies, HIV, HBV, HCV and Emerging Viruses” 158
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 158
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR 158
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 157
Prospective study of dysplastic nodes in cirrhotic patients : correlation with CT vascular pattern 157
Cholangiocarcinoma in Cirrhosis : Value of Hepatocyte Specific Magnetic Resonance Imaging 157
An unprecedented challenge: The north italian gastroenterologist response to COVID-19 155
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 150
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 149
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 147
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma 146
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients 144
Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development ofhepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. 143
Sorafenib-induced destructive thyroiditis 142
The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections 141
Reply to: Correspondence on High rates of 30-day mortality in patients with cirrhosis and COVID-19 140
Totale 22.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.899
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.899
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021200 0 0 0 0 0 0 0 0 0 0 0 200
2021/20221.743 134 114 75 130 103 92 137 160 188 237 83 290
2022/20231.956 235 193 156 224 223 366 48 128 219 30 98 36
2023/20241.564 66 101 66 100 392 97 116 101 78 96 162 189
2024/20253.428 138 373 84 326 232 95 109 328 190 364 432 757
2025/20268.177 736 497 797 564 681 510 908 414 721 631 1.124 594
Totale 26.478